Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …

Four direct‐acting oral anticoagulants (DOACs)–the thrombin inhibitor dabigatran, and the
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

Background Direct oral anticoagulants (DOACs) are the treatment of choice for most patients
with atrial fibrillation and/or noncancer-associated venous thromboembolic disease …

Background: Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory
monitoring. However, laboratory measurement may be desirable in special situations and …

Essentials• Rivaroxaban and dabigatran are substrates of the P‐glycoprotein (P‐gp)
encoded by the ABCB1 gene.• We tested the effect of ABCB1 polymorphisms and of a P‐gp …

Direct oral anticoagulant therapies, including direct anti-Xa and thrombin inhibitors have
recently been introduced and may have advantages over vitamin K antagonists such as …

Background Three novel direct oral anticoagulants (DOACs) have recently been registered
by the Food and Drug Administration and European Medicines Agency Commission …

Introduction Direct oral anticoagulant (DOAC) intra-and inter-individual variability was
previously reported, but its magnitude is still considered negligible for patient management …

In 2018, the International Council for Standardization in Haematology (ICSH) published a
consensus document providing guidance for laboratories on measuring direct oral …